NAV

Benziodarone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Benziodarone
DrugBank Accession Number
DB13277
Background

Benziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout 1. It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients 3,2.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
3D
Similar Structures
Weight
Average: 518.089
Monoisotopic: 517.88758
Chemical Formula
C17H12I2O3
Synonyms
  • Benziodarone
External IDs
  • L 2329
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
Acetylsalicylic acidThe therapeutic efficacy of Benziodarone can be decreased when used in combination with Acetylsalicylic acid.
AllopurinolThe excretion of Benziodarone can be increased when combined with Allopurinol.
BendroflumethiazideThe therapeutic efficacy of Benziodarone can be decreased when used in combination with Bendroflumethiazide.
BenzthiazideThe therapeutic efficacy of Benziodarone can be decreased when used in combination with Benzthiazide.
ChlorothiazideThe therapeutic efficacy of Benziodarone can be decreased when used in combination with Chlorothiazide.
Food Interactions
Not Available

Categories

ATC Codes
C01DX54 — Benziodarone, combinationsC01DX04 — Benziodarone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Benzofurans / O-iodophenols / Benzoyl derivatives / 3-aroylfurans / Iodobenzenes / Aryl iodides / Heteroaromatic compounds / Oxacyclic compounds / Organoiodides / Organic oxides
show 1 more
Substituents
2-halophenol / 2-iodophenol / 3-aroylfuran / Aromatic heteropolycyclic compound / Aryl halide / Aryl iodide / Aryl-phenylketone / Benzenoid / Benzofuran / Benzoyl
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
75CL65GTYR
CAS number
68-90-6
InChI Key
CZCHIEJNWPNBDE-UHFFFAOYSA-N
InChI
InChI=1S/C17H12I2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
IUPAC Name
4-(2-ethyl-1-benzofuran-3-carbonyl)-2,6-diiodophenol
SMILES
CCC1=C(C(=O)C2=CC(I)=C(O)C(I)=C2)C2=CC=CC=C2O1

References

General References
  1. Linduskova M, Vykydal M: [The importance of benziodarone in the treatment of gout and hyperuricemic syndrome]. Cas Lek Cesk. 1990 Nov 30;129(48):1524-5. [Article]
  2. Fung, M., Thornton, A., Mybeck, K., Wu, J. H., Hornbuckle, K., & Muniz, E.: Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets- 1960 to 1999 Drug Information Journal. 2001 Jan 6;35(1):293–317. [Article]
  3. G. P. Ellis, G.B. West (2011). Progress in Medicinal Chemistry, Volume 6. Butterworth-Heinemann. [ISBN:9780080862545]
ChemSpider
6001
BindingDB
50209206
ChEBI
135814
ChEMBL
CHEMBL232201
ZINC
ZINC000003875456
PDBe Ligand
PJO
Wikipedia
Benziodarone
PDB Entries
8ii1

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0139 mg/mLALOGPS
logP5.8ALOGPS
logP5.87Chemaxon
logS-4.6ALOGPS
pKa (Strongest Acidic)5.61Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area50.44 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity103.85 m3·mol-1Chemaxon
Polarizability39.84 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0000090000-8e289f6408755d5af5cc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0100090000-7ce7c65406aee33a8645
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0000090000-54fe611c1100a648c45b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0173-0509170000-ba7179984213ad4b9488
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0595-0459110000-b3c62234c83e77788cbc
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0900300000-707e7ed151b7e8a00e40
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-189.23543
predicted
DeepCCS 1.0 (2019)
[M+H]+191.70866
predicted
DeepCCS 1.0 (2019)
[M+Na]+199.0136
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:39 / Updated at February 21, 2021 18:54